登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>4-1BB Ligand >CHEK-ATP039

HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line

For research use only.

描述(Description)

HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line

应用说明(Application)

Binding assay by FACS and cell based ELISA

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (5 μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

10% DMSO + 90% FBS

装量(Quantity)

1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

活性(Bioactivity)

4-1BB Ligand FACS

FACS assay shows that Biotinylated Human 4-1BB, Fc,Avitag (41B-H82F8) can bind to HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line (CHEK-ATP039). HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell was red line, Negative control HEK293 cells was grey line (QC tested).

Protocol

 

背景(Background)

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

 

License Disclosure

This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
4-1BB Ligand靶点信息
英文全称:Tumor necrosis factor ligand superfamily member 9
中文全称:肿瘤坏死因子配体超家族成员9
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定